StockData
Amgen Inc logo

Amgen Inc (AMGN) stock

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 17/3026% above fair value
$443.89−14.04 (-3.07%)

Close on Nov 18, 2026Market cap $239.98BP/E 25.7Yield 2.18%

Amgen revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Amgen's revenue for the twelve months ending Sep 30, 2026 was $38.90B, up 8.2% year over year. For fiscal 2025 it was $36.75B, up 10.0% from the year before. Over ten years it grew 5.4% a year on average. The highest annual figure on record is $36.75B in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$36.75B+10.0%
FY2024Dec 31, 2024$33.42B+18.6%
FY2023Dec 31, 2023$28.19B+7.1%
FY2022Dec 31, 2022$26.32B+1.3%
FY2021Dec 31, 2021$25.98B+2.2%
FY2020Dec 31, 2020$25.42B+8.8%
FY2019Dec 31, 2019$23.36B-1.6%
FY2018Dec 31, 2018$23.75B+3.9%
FY2017Dec 31, 2017$22.85B-0.6%
FY2016Dec 31, 2016$22.99B+6.1%
FY2015Dec 31, 2015$21.66B+8.0%
FY2014Dec 31, 2014$20.06B+7.4%
FY2013Dec 31, 2013$18.68B+8.2%
FY2012Dec 31, 2012$17.27B+10.8%
FY2011Dec 31, 2011$15.58B+3.5%
FY2010Dec 31, 2010$15.05B+2.8%
FY2009Dec 31, 2009$14.64B-2.4%
FY2008Dec 31, 2008$15.00B+1.6%
FY2007Dec 31, 2007$14.77B–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$10.37B+8.5%
Q2 FY2026Jun 30, 2026$10.05B+9.5%
Q1 FY2026Mar 31, 2026$8.62B+5.8%
Q4 FY2025Dec 31, 2025$9.87B+8.6%
Q3 FY2025Sep 30, 2025$9.56B+12.4%
Q2 FY2025Jun 30, 2025$9.18B+9.4%
Q1 FY2025Mar 31, 2025$8.15B+9.4%
Q4 FY2024Dec 31, 2024$9.09B+10.9%
Q3 FY2024Sep 30, 2024$8.50B+23.2%
Q2 FY2024Jun 30, 2024$8.39B+20.1%
Q1 FY2024Mar 31, 2024$7.45B+22.0%
Q4 FY2023Dec 31, 2023$8.20B+19.8%
Q3 FY2023Sep 30, 2023$6.90B+3.8%
Q2 FY2023Jun 30, 2023$6.99B+5.9%
Q1 FY2023Mar 31, 2023$6.11B-2.1%
Q4 FY2022Dec 31, 2022$6.84B-0.1%
Q3 FY2022Sep 30, 2022$6.65B+12.7%
Q2 FY2022Jun 30, 2022$6.59B-0.6%
Q1 FY2022Mar 31, 2022$6.24B-2.9%
Q4 FY2021Dec 31, 2021$6.85B+10.3%
Q1 FY2021Mar 31, 2021$5.90B-4.2%
Q4 FY2020Dec 31, 2020$6.63B+13.0%
Q3 FY2020Sep 30, 2020$6.42B+15.6%
Q2 FY2020Jun 30, 2020$6.21B-0.4%
Q1 FY2020Mar 31, 2020$6.16B+4.4%
Q2 FY2019Jun 30, 2019$5.87B-3.1%
Q1 FY2019Mar 31, 2019$5.56B+0.1%
Q4 FY2018Dec 31, 2018$6.23B+11.9%
Q3 FY2018Sep 30, 2018$5.90B+2.3%
Q2 FY2018Jun 30, 2018$6.06B+4.3%
Q1 FY2018Mar 31, 2018$5.55B+1.6%
Q4 FY2017Dec 31, 2017$5.57B-1.7%
Q3 FY2017Sep 30, 2017$5.77B+4.7%
Q2 FY2017Jun 30, 2017$5.81B+6.1%
Q1 FY2017Mar 31, 2017$5.46B–
Q4 FY2016Dec 31, 2016$5.66B–
Q3 FY2016Sep 30, 2016$5.52B–
Q2 FY2016Jun 30, 2016$5.47B–

More Amgen figures

See a number that looks wrong?